Postmenopausal Osteoporosis Therapeutics Market: Global Industry Analysis and Forecast 2015 - 2021

  • To Be Published : Dec-2016 |
  • Status : Work in progress |
  • Format :

Osteoporosis is an orthopedic condition where the bone density and bone mass decreases and eventually increases the risk of bone fracture. Osteoporosis is one of the most common age related diseases worldwide and also represents a major public health problem. Osteoporosis is common among females than in the male population. Women with age more than 50 years are more prone to osteoporosis due to hormonal changes occurring after menopause. The currently available technologies fail to cure postmenopausal osteoporosis completely and thus healthcare professionals prefer medicinal therapy for treatment of postmenopausal osteoporosis. 

Considering the relation of age in postmenopausal osteoporosis, aging of population worldwide is the major factor that is increasing the morbidity rate of postmenopausal osteoporosis. Increasing prevalence of this condition and innovations in the corresponding drug market are major driving forces of the postmenopausal osteoporosis therapeutics market. While high standards for approval of any new product to launch into the market, competition from the emerging alternative technologies and intense competition from generics are restraining growth of this market.  Mergers and acquisitions taking place in the market is one of the major restraining force of postmenopausal osteoporosis therapeutics market. 

Based on the type of medicines used, postmenopausal osteoporosis therapeutics market is segmented as follows:

  • Bisphosphonates
  • Hormones
  • Strontium ranelate 
  • Raloxifene
  • Denosumab
  • Others

Geographically, the global postmenopausal osteoporosis therapeutics market is segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World

Currently, North America dominates the postmenopausal osteoporosis therapeutics market and is closely followed by Europe. Asia-Pacific is a lucrative regional market for such drugs considering factors such as increasing healthcare spending and improving healthcare infrastructure. Gradual; development of the medical tourism industry in the region is also expected to further spur the growth of postmenopausal osteoporosis therapeutics market in Asia-Pacific. Some of the major companies contributing to the global postmenopausal osteoporosis therapeutics market are Eli Lilly, Pfizer, Inc., F. Hoffman La Roche, Procter & Gamble and Merck.

Key geographies evaluated in this report are:

  • North America
    • U.S
    • Canada
  • Europe
    • France, Germany, Italy, Spain, and the UK
    • Eastern Europe
    • CIS
  • APAC
    • China
    • India
    • Japan
    • Australia
    • Others
  • Latin America
    • Argentina
    • Brazil
    • Others

Key features of this report

  • Drivers, restraints, and challenges shaping the Postmenopausal Osteoporosis Therapeutics market dynamics
  • Latest innovations and key events in the industry
  • Analysis of business strategies of the top players
  • Postmenopausal Osteoporosis Therapeutics market estimates and forecasts(2015 -2021)
Back To Top